Characterization and Stability Study of Amniotic Membrane Stem Cell Metabolite Product (AMSC-MP)

Sari, Diah Indah Kumala; Erawati, Tristiana; Miatmoko, Andang; Prakoeswa, Cita Rosita Sigit; Soeratri, Widji

doi:10.21276/ijprhs.2020.01.02

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, AMSC-MP liquid did not show color changes or an odor at cold temperatures. Its pH was 7-7.5 without significant changes during storage for 28 days [19].…”

Section: Physicochemical Properties and Stability Of Amsc-mpmentioning

confidence: 98%

“…AMSC-MP is a clear liquid containing various proteins, and some products form yellowish white lyophilized powder. A study by Kumala et al (2020) compared the physicochemical stability of AMSC-MP in two forms, i.e., native AMSC-MP liquid and lyophilized AMSC-MP powder [19]. The results showed that AMSC-MP liquid began to change color after 7 days of storage at room temperature.…”

Section: Physicochemical Properties and Stability Of Amsc-mpmentioning

confidence: 99%

“…Freeze-dried AMSC-MP has high crystallinity, which was supported by a scanning electron microscopy characterization showing a tetragonal crystal shape. The crystals have a melting point of 163.8 °C [19].…”

Section: Physicochemical Properties and Stability Of Amsc-mpmentioning

confidence: 99%

“…Fig.1Qualitative determination of protein markers in fluid and freeze-dried (FD) AMSC-MP analysed using SDS-PAGE[19] …”

mentioning

confidence: 99%

See 3 more Smart Citations

Prospective use of amniotic mesenchymal stem cell metabolite products for tissue regeneration

Miatmoko

Hariawan²,

Cahyani³

et al. 2023

J Biol Eng

Self Cite

View full text Add to dashboard Cite

Chronic disease can cause tissue and organ damage constituting the largest obstacle to therapy which, in turn, reduces patients’ quality-adjusted life-year. Degenerative diseases such as osteoporosis, Alzheimer’s disease, Parkinson’s disease, and infectious conditions such as hepatitis, cause physical injury to organs. Moreover, damage resulting from chronic conditions such as diabetes can also culminate in the loss of organ function. In these cases, organ transplantation constitutes the therapy of choice, despite the associated problems of immunological rejection, potential disease transmission, and high morbidity rates. Tissue regeneration has the potential to heal or replace tissues and organs damaged by age, disease, or trauma, as well as to treat disabilities. Stem cell use represents an unprecedented strategy for these therapies. However, product availability and mass production remain challenges. A novel therapeutic alternative involving amniotic mesenchymal stem cell metabolite products (AMSC-MP) has been developed using metabolites from stem cells which contain cytokines and growth factors. Its potential role in regenerative therapy has recently been explored, enabling broad pharmacological applications including various gastrointestinal, lung, bladder and renal conditions, as well as the treatment of bone wounds, regeneration and skin aging due to its low immunogenicity and anti-inflammatory effects. The various kinds of growth factors present in AMSC-MP, namely bFGF, VEGF, TGF-β, EGF and KGF, have their respective functions and activities. Each growth factor is formed by different proteins resulting in molecules with various physicochemical properties and levels of stability. This knowledge will assist in the manufacture and application of AMSC-MP as a therapeutic agent.

show abstract

“…In contrast, AMSC-MP liquid did not show color changes or an odor at cold temperatures. Its pH was 7-7.5 without significant changes during storage for 28 days [19].…”

Section: Physicochemical Properties and Stability Of Amsc-mpmentioning

confidence: 98%

Section: Physicochemical Properties and Stability Of Amsc-mpmentioning

confidence: 99%

Section: Physicochemical Properties and Stability Of Amsc-mpmentioning

confidence: 99%

“…Fig.1Qualitative determination of protein markers in fluid and freeze-dried (FD) AMSC-MP analysed using SDS-PAGE[19] …”

mentioning

confidence: 99%

See 2 more Smart Citations

Prospective use of amniotic mesenchymal stem cell metabolite products for tissue regeneration

Miatmoko

Hariawan²,

Cahyani³

et al. 2023

J Biol Eng

Self Cite

View full text Add to dashboard Cite

show abstract

“…TGF-β is a multifunctional growth factor that is essential in modulating cellular behaviour. [13][14][15] Combined therapy with topical AMSC-MP and Er:YAG fractional lasers is expected to synergistically improve treatment for vaginal laxity. AMSC-MP treatment after ablative fractional laser treatment has been used in skin rejuvenation therapy and laser-assisted drug delivery (LADD).…”

Section: Introductionmentioning

confidence: 99%

Experimental Analysis of Vaginal Laxity in Rats Treated With a Combination of Er:YAG Fractional Lasers and AMSC-MP

et al. 2023

View full text Add to dashboard Cite

Introduction: Vaginal laxity, a symptom of pelvic floor dysfunction observed in women, has many negative biological and psychological impacts. Laser treatments and stem cell-based therapies are emerging therapeutic methods for treating this condition. This study aimed to determine changes in vaginal laxity in model rats using a combination therapy of erbium-doped yttrium aluminium garnet (Er:YAG) fractional lasers and topical treatment with amniotic membrane stem cell metabolite products (AMSC-MP). Methods: The experimental animal population comprised 36 female white rats (Rattus norvegicus; 2-day-post-vaginal-delivery rats) allocated into the following four groups (n=9): K1, untreated two-day-post-vaginal-delivery rats; K2, two-day-post-vaginal-delivery rats treated with topical gel without AMSC-MP; P1, two-day-post-vaginal-delivery rats treated with Er:YAG fractional lasers and topical gel without AMSC-MP; P2, two-day-post-vaginal-delivery rats treated with Er: YAG fractional lasers and topical gel containing AMSC-MP. Immunohistochemical (IHC) examination was carried out for the expression and activity of heat shock protein 70 (HSP-70), collagen-1, tissue inhibitors of metalloproteinase 1 (TIMP-1) and matrix metalloproteinase 1 (MMP-1), as well as vaginal mucosal thickness. Results: There was a significant difference (P<0.05) in the expression of HSP-70 among all groups except K2 and P1 (P>0.05); there was no significant difference in type I collagen and TIMP-1 expression between the groups (P>0.05); there was a significant difference (P<0.05) in MMP-1 activity, with the activity in the K2 group (5.79±0.83) being higher than that in the P1 group (4.44±1.82) and that in the K1 group (5.74±1.03) being higher than that in the P2 group (4.24±1.55). Also, there was a significant difference in the thickness of the vaginal mucosa in all groups except K2 and P1 (P>0.05). Conclusion: Er:YAG fractional laser and AMSC-MP combination therapy improved vaginal laxity in model rats by increasing Hsp70 expression and vaginal mucosal thickness and decreasing MMP-1 activity.

show abstract

Dissolving microneedle patches for delivery of amniotic mesenchymal stem cell metabolite products for skin regeneration in UV-aging induced mice

Miatmoko,

Sarasitha Hariawan,

Maulidya Cahyani

et al. 2024

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Characterization and Stability Study of Amniotic Membrane Stem Cell Metabolite Product (AMSC-MP)

Cited by 4 publications

References 0 publications

Prospective use of amniotic mesenchymal stem cell metabolite products for tissue regeneration

Prospective use of amniotic mesenchymal stem cell metabolite products for tissue regeneration

Experimental Analysis of Vaginal Laxity in Rats Treated With a Combination of Er:YAG Fractional Lasers and AMSC-MP

Dissolving microneedle patches for delivery of amniotic mesenchymal stem cell metabolite products for skin regeneration in UV-aging induced mice

Contact Info

Product

Resources

About